| Designer vaccine nanodiscs for personalized cancer immunotherapy R Kuai, LJ Ochyl, KS Bahjat, A Schwendeman, JJ Moon Nature materials 16 (4), 489-496, 2017 | 940 | 2017 |
| Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer J Nam, S Son, LJ Ochyl, R Kuai, A Schwendeman, JJ Moon Nature communications 9 (1), 1074, 2018 | 684 | 2018 |
| Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures H He, L Liu, EE Morin, M Liu, A Schwendeman Accounts of chemical research 52 (9), 2445-2461, 2019 | 404 | 2019 |
| High-density lipoproteins: nature’s multifunctional nanoparticles R Kuai, D Li, YE Chen, JJ Moon, A Schwendeman ACS nano 10 (3), 3015-3041, 2016 | 317 | 2016 |
| Elimination of established tumors with nanodisc-based combination chemoimmunotherapy R Kuai, W Yuan, S Son, J Nam, Y Xu, Y Fan, A Schwendeman, JJ Moon Science advances 4 (4), eaao1736, 2018 | 286 | 2018 |
| The acidic microclimate in poly (lactide-co-glycolide) microspheres stabilizes camptothecins A Shenderova, TG Burke, SP Schwendeman Pharmaceutical research 16, 241-248, 1999 | 283 | 1999 |
| Injectable controlled release depots for large molecules SP Schwendeman, RB Shah, BA Bailey, AS Schwendeman Journal of Controlled Release 190, 240-253, 2014 | 255 | 2014 |
| High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme P Kadiyala, D Li, FM Nuñez, D Altshuler, R Doherty, R Kuai, M Yu, ... ACS nano 13 (2), 1365-1384, 2019 | 191 | 2019 |
| Engineering patient-specific cancer immunotherapies L Scheetz, KS Park, Q Li, PR Lowenstein, MG Castro, A Schwendeman, ... Nature biomedical engineering 3 (10), 768-782, 2019 | 153 | 2019 |
| Stabilization of 10-hydroxycamptothecin in poly (lactide-co-glycolide) microsphere delivery vehicles A Shenderova, TG Burke, SP Schwendeman Pharmaceutical research 14, 1406-1414, 1997 | 150 | 1997 |
| High-density lipoproteins during sepsis: from bench to bedside S Tanaka, D Couret, A Tran-Dinh, J Duranteau, P Montravers, ... Critical Care 24, 1-11, 2020 | 144 | 2020 |
| HDL in sepsis–risk factor and therapeutic approach EE Morin, L Guo, A Schwendeman, XA Li Frontiers in pharmacology 6, 158346, 2015 | 127 | 2015 |
| Predicting drug release kinetics from nanocarriers inside dialysis bags M Yu, W Yuan, D Li, A Schwendeman, SP Schwendeman Journal of Controlled Release 315, 23-30, 2019 | 124 | 2019 |
| Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy R Kuai, X Sun, W Yuan, LJ Ochyl, Y Xu, AH Najafabadi, L Scheetz, MZ Yu, ... Journal of controlled release 282, 131-139, 2018 | 120 | 2018 |
| Battle of GLP-1 delivery technologies M Yu, MM Benjamin, S Srinivasan, EE Morin, EI Shishatskaya, ... Advanced drug delivery reviews 130, 113-130, 2018 | 118 | 2018 |
| Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers SP Schwendeman, G Zhu, H Bentz, JA Hubbell, W Jiang, A Shenderova, ... US Patent 6,743,446, 2004 | 107 | 2004 |
| The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties [S] A Schwendeman, DO Sviridov, W Yuan, Y Guo, EE Morin, Y Yuan, ... Journal of lipid research 56 (9), 1727-1737, 2015 | 103 | 2015 |
| Prediction of microclimate pH in poly (lactic-co-glycolic acid) films AG Ding, A Shenderova, SP Schwendeman Journal of the American Chemical Society 128 (16), 5384-5390, 2006 | 92 | 2006 |
| Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice P Kadiyala, SV Carney, JC Gauss, MB Garcia-Fabiani, S Haase, ... The Journal of clinical investigation 131 (4), 2021 | 90 | 2021 |
| Synthetic high-density lipoprotein-mediated targeted delivery of liver X receptors agonist promotes atherosclerosis regression Y Guo, W Yuan, B Yu, R Kuai, W Hu, EE Morin, MT Garcia-Barrio, J Zhang, ... EBioMedicine 28, 225-233, 2018 | 89 | 2018 |
